E. Marilyn Schaeffer

E. Marilyn Schaeffer's AcademicInfluence.com Rankings

Medical

#3388

Historical Rank

Oncology

#207

Historical Rank

medical Degrees

Download Badge

Medical

E. Marilyn Schaeffer's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is E. Marilyn Schaeffer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

E. Marilyn Schaeffer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (1026)
PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes (2000) (904)
Complications after prostate biopsy: data from SEER-Medicare. (2011) (653)
Prostate Cancer, Version 1.2016. (2016) (586)
Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. (1999) (440)
PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. (2000) (385)
Complications After Systematic, Random, and Image-guided Prostate Biopsy. (2017) (335)
Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology (2014) (277)
Prostate cancer, version 2.2014. (2014) (252)
Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. (2019) (236)
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? (2013) (228)
Increasing incidence of metastatic prostate cancer in the United States (2004–2013) (2016) (223)
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. (2012) (219)
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. (2016) (209)
Mutation of Tec family kinases alters T helper cell differentiation (2001) (204)
Pre-processing Agilent microarray data (2007) (203)
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. (2021) (201)
Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations (2017) (200)
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy (2017) (193)
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. (2016) (163)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. (2017) (158)
Tec Family Kinases Modulate Thresholds for Thymocyte Development and Selection (2000) (157)
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer (2008) (154)
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. (2015) (135)
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy (2013) (134)
What are the outcomes of radical prostatectomy for high-risk prostate cancer? (2009) (133)
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target (2018) (133)
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. (2017) (133)
Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. (2014) (133)
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. (2016) (131)
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. (2015) (127)
Tec family kinases in lymphocyte signaling and function. (2000) (107)
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis (2016) (106)
High anterior release of the levator fascia improves sexual function following open radical retropubic prostatectomy. (2008) (104)
rlk/TXK Encodes Two Forms of a Novel Cysteine String Tyrosine Kinase Activated by Src Family Kinases (1999) (93)
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. (2017) (89)
Very high risk localized prostate cancer: definition and outcomes (2013) (86)
Gene expression pathways of high grade localized prostate cancer (2011) (85)
Oxygenation in status asthmaticus improves during ventilation with helium-oxygen. (1999) (83)
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program (2019) (82)
TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. (2017) (82)
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup (2017) (81)
The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. (2017) (81)
The evolving genomic landscape of urothelial carcinoma (2017) (81)
Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. (2016) (78)
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. (2012) (78)
Germline and Somatic Mutations in Prostate Cancer for the Clinician. (2019) (78)
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression (2015) (76)
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. (2018) (74)
Prostate Specific Membrane Antigen Targeted 18F‐DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study (2018) (74)
Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. (2017) (72)
Active Surveillance for Prostate Cancer. (2017) (71)
A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. (2011) (69)
Long-term oncologic outcome after laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma. (2007) (67)
Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. (2007) (65)
Reclassification rates are higher among African American men than Caucasians on active surveillance. (2015) (64)
Re: Extended-spectrum β-lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. (2012) (63)
USE OF THE PROSTATE HEALTH INDEX FOR DETECTION OF PROSTATE CANCER: RESULTS FROM A LARGE ACADEMIC PRACTICE (2016) (63)
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. (2017) (60)
Racial Differences in Genomic Profiling of Prostate Cancer. (2020) (59)
Prostate specific antigen testing among the elderly--when to stop? (2008) (59)
Urothelial carcinoma: Stem cells on the edge (2009) (59)
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality (2017) (58)
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. (2010) (58)
Association of Tumor Infiltrating T-cell Density with Molecular Subtype, Racial Ancestry and Clinical Outcomes in Prostate Cancer (2018) (57)
Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer (2017) (57)
Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. (2014) (57)
Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. (2016) (57)
Re: long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. (2011) (57)
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. (2020) (57)
Sox9 is required for prostate development and prostate cancer initiation (2012) (56)
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas (2015) (56)
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. (2021) (55)
Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. (2018) (54)
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells (2012) (53)
Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. (2015) (53)
Wnt signaling though beta-catenin is required for prostate lineage specification. (2012) (53)
Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. (2017) (52)
Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30‐year experience (2013) (52)
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome (2012) (50)
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer (2019) (50)
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer (2020) (46)
Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase‐inhibiting therapy (2009) (46)
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. (2020) (46)
Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes (2021) (45)
Contemporaneous comparison of open vs minimally‐invasive radical prostatectomy for high‐risk prostate cancer (2013) (45)
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. (2017) (45)
Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. (2016) (44)
Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy (2012) (44)
The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma. (2009) (44)
Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancer (2012) (43)
The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer (2015) (43)
Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience (2015) (43)
SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. (2016) (41)
Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? (2010) (41)
Xanthogranulomatous pyelonephritis: presentation and management in the era of laparoscopy (2009) (40)
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer (2018) (39)
Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential (2017) (38)
Genetic regulation of prostate development. (2011) (38)
Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy. (2009) (38)
Clinical sequelae of radiographic iceball involvement of collecting system during computed tomography-guided percutaneous renal tumor cryoablation. (2006) (37)
Laparoscopic radical nephrectomy for patients with pathologic T3b renal-cell carcinoma: the Johns Hopkins experience. (2009) (36)
Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers (2018) (36)
Incidence of local recurrence and port site metastasis after laparoscopic radical nephroureterectomy. (2007) (35)
Inflammatory Bowel Disease and the Risk of Prostate Cancer. (2018) (35)
A PRC2-independent function for EZH2 in regulating rRNA 2′-O methylation and IRES-dependent translation (2021) (35)
Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer1 (2016) (34)
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer (2020) (34)
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences (2021) (33)
Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database (2017) (33)
Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. (2015) (32)
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination (2017) (32)
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. (2016) (31)
Perioperative outcomes of elderly patients undergoing laparoscopic renal procedures. (2009) (30)
TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. (2019) (29)
Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review (2017) (28)
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? (2019) (28)
Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases (2017) (28)
The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013). (2017) (27)
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer (2015) (27)
Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer (2018) (27)
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. (2009) (27)
Urinary markers in the detection of bladder cancer: what's new? (2006) (27)
Laparoscopic retroperitoneal lymph node dissection: duplication of open technique. (2005) (27)
Molecular effects of genistein on male urethral development. (2011) (27)
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. (2018) (27)
Gender Representation in Urologic Subspecialties. (2018) (26)
Can ischemic preconditioning ameliorate renal ischemia-reperfusion injury in a single-kidney porcine model? (2008) (25)
Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk (2016) (25)
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. (2016) (25)
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients. (2017) (24)
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment (2018) (23)
Contemporary management of men with high-risk localized prostate cancer in the United States (2017) (23)
Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. (2015) (22)
Oncologic outcomes of extravesical stapling of distal ureter in laparoscopic nephroureterectomy. (2007) (22)
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets (2021) (22)
Radical Retropubic and Perineal Prostatectomy (2012) (21)
Laparoscopic radical nephroureterectomy with en-bloc distal ureteral and bladder cuff excision using a single position pneumovesicum method. (2008) (21)
Whole genome microarray of the major pelvic ganglion after cavernous nerve injury: new insights into molecular profile changes after nerve injury (2012) (21)
Contemporary management of men with high-risk localized prostate cancer in the United States (2017) (21)
Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)–Induced Cancer at Multiple Sites (2015) (21)
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy (2017) (20)
HES6 promotes prostate cancer aggressiveness independently of Notch signalling (2015) (20)
Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance (2020) (20)
Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. (2016) (19)
African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. (2019) (19)
The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. (2019) (19)
Duplex ultrasonography detects clinically significant anomalies of penile arterial vasculature affecting surgical approach to penile straightening. (2005) (19)
Biochemical and genetic analyses of the Tec kinases Itk and Rlk/Txk. (2001) (18)
Outcomes of men with an elevated prostate‐specific antigen (PSA) level as their sole preoperative intermediate‐ or high‐risk feature (2014) (18)
Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer (2017) (18)
Evolution of the clinical presentation of men undergoing radical prostatectomy for high‐risk prostate cancer (2012) (18)
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. (2011) (17)
Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer (2018) (17)
Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy (2018) (17)
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. (2010) (16)
Inguinal bladder hernia. (2003) (16)
Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. (2019) (16)
Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis (2022) (15)
Paraneoplastic polyarthritis from non-small-cell lung cancer metastatic to the bladder. (2007) (15)
Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity (2011) (15)
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. (2020) (15)
The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. (2016) (15)
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway (2019) (15)
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma (2019) (15)
Risks of testosterone replacement. (2004) (15)
CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer (2020) (14)
Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials (2018) (14)
Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. (2017) (14)
The case for open radical prostatectomy. (2010) (14)
Surgical Versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. (2019) (14)
A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort (2019) (14)
Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials (2022) (13)
Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. (2019) (13)
Implementation of a Surgeon‐Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy (2017) (12)
Risk factors, prevention and early detection of prostate cancer. (2009) (12)
Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis (2021) (12)
Prostate cancer in sexual minorities and the influence of HIV status (2019) (12)
Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. (2022) (12)
Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. (2019) (11)
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients (2017) (11)
Amyloidosis of the seminal vesicle and hematospermia. (2004) (11)
Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20‐year institutional experience (2013) (11)
Association between inflammatory bowel disease and prostate cancer: A large‐scale, prospective, population‐based study (2020) (11)
United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015 (2019) (11)
The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years (2019) (11)
SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy (2019) (11)
Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer (2020) (10)
Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer (2018) (10)
The vanishing prostate cancer phenomenon. (2010) (10)
Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer (2018) (10)
Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy (2016) (10)
Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes (2020) (10)
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier (2020) (9)
Changes in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men (2020) (9)
Prophylactic use of antimicrobials in commonly performed outpatient urologic procedures (2006) (9)
Increased expression of nestin in the major pelvic ganglion following cavernous nerve injury (2012) (9)
Current recommendations for prostate cancer genetic testing: NCCN prostate guideline. (2019) (9)
Active surveillance for African-American men with prostate cancer: proceed with caution. Con. (2014) (9)
Transcriptional landscape of PTEN loss in primary prostate cancer (2020) (9)
Performance of Prostate Health Index (PHI) in Biopsy-Naïve Black Men. (2020) (8)
Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions. (2015) (8)
Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). (2017) (8)
Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy. (2014) (8)
Intraperitoneal effects of extraperitoneal laparoscopic radical prostatectomy. (2008) (8)
High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer (2015) (8)
Risk factors for infection after prostate biopsy in the United States. (2019) (7)
Educational material on prostate cancer screening is overly complex and fails to meet recommended layperson readability guidelines. (2020) (7)
Genomic and clinical characterization of stromal infiltration markers in prostate cancer (2020) (7)
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. (2022) (7)
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. (2021) (7)
Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. (2020) (7)
Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer (2022) (7)
The Effect of Local Antibiogram-based Augmented Antibiotic Prophylaxis on Infection-related Complications Following Prostate Biopsy. (2019) (7)
Pyeloduodenal fistula due to advanced upper tract malignancy. (2007) (7)
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer (2011) (6)
PD30-10 DEFINITIVE AND SUSTAINED INCREASE IN PROSTATE CANCER METASTASES IN THE UNITED STATES (2019) (5)
Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis. (2021) (5)
Reporting of Racial Health Disparities Research: Are We Making Progress? (2021) (5)
A transcriptomic model for homologous recombination deficiency in prostate cancer (2021) (5)
Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified? (2015) (5)
A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host (2019) (5)
A novel immunocompetent model of metastatic prostate cancer‐induced bone pain (2020) (5)
Using Multimethod Research Techniques to Study College Student Culture. (1987) (5)
Re: Prevalence of Sexual Dysfunction in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Meta-Analysis. (2017) (5)
Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. (2013) (5)
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. (2016) (5)
It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety? (2021) (4)
Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility. (2016) (4)
TMPRSS2‐ERG fusion impacts anterior tumor location in men with prostate cancer (2020) (4)
141 GENE EXPRESSION PATHWAYS OF HIGH GRADE LOCALIZED PROSTATE CANCER (2011) (4)
Re: Maternal and Neonatal Consequences of Treated and Untreated Asymptomatic Bacteriuria in Pregnancy: A Prospective Cohort Study with an Embedded Randomised Controlled Trial. (2016) (4)
Urological radiographic manifestations of the Ehlers-Danlos syndrome. (2007) (4)
Luminal and basal subtyping of prostate cancer. (2017) (4)
Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study (2020) (4)
Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. (2020) (4)
Re: The Preventive Antibiotics in Stroke Study (PASS): A Pragmatic Randomised Open-Label Masked Endpoint Clinical Trial. (2016) (4)
2096 HOW SAFE IS PROSTATE BIOPSY? RATE OF COMPLICATIONS REQUIRING HOSPITALIZATION FOLLOWING PROSTATE BIOPSY IN SEER-MEDICARE (2010) (4)
Application of Evicel to cavernous nerves of the rat does not influence erectile function in vivo. (2008) (4)
Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk. (2017) (4)
National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. (2019) (4)
Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol 2015;67:157-64. (2015) (4)
Performance of prostate health index and PSA density in a diverse biopsy‐naïve cohort with mpMRI for detecting significant prostate cancer (2021) (4)
Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues. (2017) (4)
Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass. (2018) (4)
Grade Migration of Prostate Cancer in the United States during the last decade. (2022) (4)
Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer. (2017) (3)
1465 OUTCOMES OF MEN WITH AN ELEVATED PSA AS THEIR SOLE PREOPERATIVE INTERMEDIATE OR HIGH RISK FEATURE (2011) (3)
MP51-05 RECLASSIFICATION RATES ARE HIGHER AMONG AFRICAN AMERICAN MEN THAN WHITE MEN ON ACTIVE SURVEILLANCE (2014) (3)
Long-Term Survival after Radical Prostatectomy for men with High Gleason Sum in the Pathological Specimen (2010) (3)
Identification and Validation of Intrinsic Subtypes of Prostate Cancer. (2016) (3)
Re: Bacteriuria and Urinary Tract Infection after Female Urodynamic Studies: Risk Factors and Microbiological Analysis. (2017) (3)
Radical prostatectomy: Surgical perspectives (2014) (3)
Long Term-Survival after Radical Prostatectomy for men with High Gleason Sum. (2010) (3)
Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk. (2016) (3)
Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes (2017) (3)
Local anaesthetic techniques for performing transperineal prostate biopsy (2021) (3)
Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. (2009) (3)
Re: lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. (2013) (3)
Re: Once-Daily Plazomicin for Complicated Urinary Tract Infections. (2019) (3)
Re: Impact of a Computerized Decision Support System on Compliance with Guidelines on Antibiotics Prescribed for Urinary Tract Infections in Emergency Departments: A Multicentre Prospective before-and-after Controlled Interventional Study. (2016) (2)
MP6-03 A NOVEL BIOMARKER SIGNATURE WHICH MAY PREDICT AGGRESSIVE DISEASE IN AFRICAN-AMERICAN MEN WITH PROSTATE CANCER (2015) (2)
MP55-18 RACE IMPACTS ETS FAMILY TRANSCRIPTION FACTOR EXPRESSION IN PROSTATE CANCER: DATA FROM A MULTI-INSTITUTIONAL COHORT (2015) (2)
MP50-18 STUDY OF PSMA-TARGETED 18F-DCFPYL PET/CT IN THE EVALUATION OF MEN WITH AN ELEVATED PSA FOLLOWING RADICAL PROSTATECTOMY (2016) (2)
Re: Urinary tract infection in male veterans: treatment patterns and outcomes. (2013) (2)
THE REVIVAL OF PHYSICAL EDUCATION AND PRACTICAL HYGIENE (1891) (2)
Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy. (2016) (2)
Re: Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized double-blind placebo-controlled trial. (2012) (2)
Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer. (2020) (2)
Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. (2015) (2)
Re: Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. (2017) (2)
Stereotactic Ablative Radiation Therapy for the Treatment of Oligometastatic Prostate Cancer (2016) (2)
Re: Levofloxacin for BK Virus Prophylaxis following Kidney Transplantation: A Randomized Clinical Trial. (2015) (2)
Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. (2020) (2)
Re: Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. (2015) (2)
Iatrogenic Extraprostatic Extension of Prostate Cancer From a Needle Biopsy (2015) (2)
Re: Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada. (2013) (2)
Re: Chronic prostatitis does not influence urinary PCA3 score. (2012) (2)
Re: The humoral pattern recognition molecule PTX3 is a key component of innate immunity against urinary tract infection. (2015) (2)
Re: The influence of urinary pH on antibiotic efficacy against bacterial uropathogens. (2015) (2)
Cystoscopic management of an extruded coil from arteriovenous fistula embolization using arthroscopic instruments. (2008) (2)
United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015 (2019) (2)
Re: Pre- and Postoperative Predictors of Infection-Related Complications in Patients Undergoing Percutaneous Nephrolithotomy. (2018) (2)
Association between surgical approach and survival following resection of abdominopelvic malignancies (2020) (2)
MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION (2019) (2)
Re: Similarity and divergence of phylogenies, antimicrobial susceptibilities, and virulence factor profiles of Escherichia coli isolates causing recurrent urinary tract infections that persist or result from reinfection. (2013) (2)
The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study (2018) (2)
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer (2016) (2)
Re: IL17 Mediates Pelvic Pain in Experimental Autoimmune Prostatitis (EAP). (2016) (2)
Re: Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010. (2012) (2)
Oral Scientific SessionsDevelopment and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk (2017) (2)
Re: Escherichia coli Isolates from Patients with Bacteremic Urinary Tract Infection are Genetically Distinct from Those Derived from Sepsis following Prostate Transrectal Biopsy. (2017) (2)
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences (2021) (1)
Re: Defining a Clinically Significant Struvite Stone: A Non-Randomized Retrospective Study. (2020) (1)
Rebuttal from authors re: Peter Albers. Quality criteria of laparoscopic nephroureterectomy. Eur Urol. 2007;51:1481-2. (2007) (1)
Re: Infections after Fiducial Marker Implantation for Prostate Radiotherapy: Are we Underestimating the Risks? (2016) (1)
Re: ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. (2013) (1)
Prostate Cancer: Localized: Radiation TherapyMP14-12 EFFICACY OF EARLY AND DELAYED RADIATION IN A PROSTATECTOMY COHORT ADJUSTED FOR GENOMIC AND CLINICAL RISK (2016) (1)
Re: Urologic Chronic Pelvic Pain Syndrome: Insights from the MAPP Research Network. (2020) (1)
Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise. (2015) (1)
Re: Bladder Emptying Method is the Primary Determinant of Urinary Tract Infections in Patients with Spinal Cord Injury: Results from a Prospective Rehabilitation Cohort Study. (2020) (1)
MP07-15 UTILITY OF PTEN/ERG STATUS IN A CONTEMPORARY COHORT OF MEN WITH FAVORABLE-RISK PROSTATE CANCERS (2016) (1)
targeted 18 F-DCFPyL PET / CT in the Preoperative Staging of Men with High-risk Prostate Cancer : Results of a Prospective Phase II Single-Center Study (2017) (1)
Re: Development of a Urinary-Specific Antibiogram for Gram-Negative Isolates: Impact of Patient Risk Factors on Susceptibility. (2015) (1)
Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment (2018) (1)
Re: Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. (2015) (1)
Re: demographic, behavioral, and clinical characteristics of men with nongonococcal urethritis differ by etiology: a case-comparison study. (2012) (1)
Re: Screening for Asymptomatic Bacteruria at One Month after Adult Kidney Transplantation: Clinical Factors and Implications. (2018) (1)
Re: Norwegian Patients and Retail Chicken Meat Share Cephalosporin-Resistant Escherichia coli and IncK/blaCMY-2 Resistance Plasmids. (2018) (1)
Re: Whole-Genome Sequencing of Uropathogenic Escherichia coli Reveals Long Evolutionary History of Diversity and Virulence. (2017) (1)
Re: Comparison of Host Response Mechanisms Evoked by Extended Spectrum Beta Lactamase (ESBL)—and Non-ESBL-Producing Uropathogenic E. coli (2014) (1)
Re: Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. (2012) (1)
Re: Intracellular Uropathogenic E. coli Exploits Host Rab35 for Iron Acquisition and Survival within Urinary Bladder Cells. (2016) (1)
Re: Selective Depletion of Uropathogenic E. coli from the Gut by a FimH Antagonist. (2018) (1)
Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery (2019) (1)
The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy. (2016) (1)
Progress in Prognosis and Prediction for Men with Prostate Cancer. (2017) (1)
Re: Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. (2012) (1)
Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy. (2013) (1)
Re: antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. (2013) (1)
Re: Toll-like 4 receptor variant, Asp299Gly, and reduced risk of hemorrhagic cystitis after hematopoietic stem cell transplantation. (2013) (1)
Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests. (2020) (1)
Nonspecific Presentation of a Multiloculated Prostatic Abscess After Transurethral Prostatic Biopsy for Elevated Prostate-specific Antigen Level (2014) (1)
Re: origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. (2012) (1)
Identification and Validation of PCAT 14 as Prognostic Biomarker in Prostate Cancer 1 (2016) (1)
Prostate Cancer: Epidemiology & Natural History IIIMP78-19 RACIAL DISPARITIES IN ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY: LONG-TERM FOLLOW-UP (2014) (1)
Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure. (2016) (1)
Development and validation of genomic signature to predict ADT treatment failure. (2016) (1)
847 HES6 promotes prostate cancer aggressiveness and is independent of Notch signalling (2014) (1)
Race, demographics, and socioeconomics as they relate to newly diagnosed metastatic prostate cancer in the United States. (2017) (1)
Re: Bacterial Resistance in Urinary Tract Infections in Patients with Diabetes Matched with Patients without Diabetes. (2017) (1)
A 24-Gene Predictor of Response to Postoperative Radiation Therapy in Prostate Cancer. (2016) (1)
Re: Effectiveness of Diet, Sexual Habits and Lifestyle Modifications on Treatment of Chronic Pelvic Pain Syndrome. (2015) (1)
Re: Postoperative Urinary Retention in Men is Common after Carotid Endarterectomy and is Associated with Advanced Age and Prior Urinary Tract Infection. (2017) (1)
73: Xanthogranulomatous Pyelonephritis: Presentation and Surgical Management in the Laparoscopic ERA (2005) (1)
Re: Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections. (2013) (1)
Re: Effects of Perioperative Supplementation with Pro-/Synbiotics on Clinical Outcomes in Surgical Patients: A Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials. (2017) (1)
Re: Role of Gram-Positive Bacteria in Chronic Pelvic Pain Syndrome (CPPS). (2020) (1)
Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients. (2016) (1)
Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). (2021) (1)
2229 COMPARISON OF CLINICAL AND GENOMIC MODELS FOR PREDICTION OF RAPID METASTATIC DISEASE AFTER RADICAL PROSTATECTOMY (2013) (1)
Re: a FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. (2014) (1)
Re: Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship. (2017) (1)
Re: Simple cystectomy: outcomes of a new operative technique. (2012) (1)
435 Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk (2016) (1)
OUTCOMES OF PATIENTS FOLLOWING PANCREATIC RESECTION FOR ISOLATED RENAL CELL CARCINOMA METASTASIS (2009) (1)
Does primary androgen-deprivation therapy improve survival for localized prostate cancer? (2008) (1)
GENOMIC CLASSIFIER AUGMENTS THE ROLE OF PATHOLOGICAL FEATURES IN IDENTIFYING OPTIMAL CANDIDATES FOR ADJUVANT RADIATION THERAPY IN PATIENTS WITH PROSTATE CANCER: DEVELOPMENT AND INTERNAL VALIDATION OF A MULTIVARIABLE PROGNOSTIC MODEL: PD72‐02 (2017) (1)
MP53-17 INCREASING INCIDENCE OF INFECTIONS AFTER PROSTATE BIOPSY IN THE UNITED STATES (2019) (1)
Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier (2020) (1)
Re: Risk Factors and Outcomes of Surgical Site Infection in Children (2012) (1)
Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate (2020) (1)
Re: Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. (2013) (1)
Re: Intermingled Klebsiella pneumoniae Populations between Retail Meats and Human Urinary Tract Infections. (2017) (1)
LAPAROSCOPIC RADICAL NEPHROURETERECTOMY: THE INCIDENCE OF LOCAL RECURRENCE AND PORT SITE METASTASIS (2006) (1)
Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials. (2022) (1)
NCCN Prostate Cancer , Version 2 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
PD07-07 MOLECULAR SUBTYPING OF >80,000 PROSTATE CANCER TRANSCRIPTOMES IDENTIFIES FOUR CLASSES WITH DISTINCT BIOLOGICAL AND CLINICAL CHARACTERISTICS WITH IMPLICATIONS FOR TARGETED THERAPIES (2022) (1)
Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. (2018) (1)
Re: Enterococcus faecalis subverts and invades the host urothelium in patients with chronic urinary tract infection. (2015) (1)
Real-world use of MRI for risk stratification prior to prostate biopsy. (2022) (1)
AFTER SYSTEMATIC , RANDOM AND IMAGE-GUIDED PROSTATE BIOPSY (2016) (1)
Re: Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a case-control study. (2015) (1)
Multiple Intermediate-Risk Factors as a Prognostic Tool for Men With Localized Prostate Cancer (2014) (1)
Psychosocial factors and treatment satisfaction after radical prostatectomy (2016) (1)
MP44-10 THE VALUE OF DYNAMIC CONTRAST ENHANCEMENT FOR RISK-STRATIFICATION AND PROSTATE CANCER DETECTION ON MULTIPARAMETRIC PROSTATE MRI (2023) (0)
Re: Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndrome (2013) (0)
MP51-09 ASSOCIATION BETWEEN LOW TESTOSTERONE AND PERIOPERATIVE OUTCOMES IN PATIENTS UNDERGOING TRANSURETHRAL PROSTATE SURGERY (2023) (0)
MP40-19 WEST-AFRICAN ANCESTRY CAN AID PREDICTION OF HIGH-GRADE PROSTATE CANCER IN BLACK-TAILORED RISK CALCULATOR (2023) (0)
PD04-04 MOLECULAR CORRELATES WITH PSMA EXPRESSION IN PROSTATE CANCER (2023) (0)
Tumors Cyclin D 1 Loss Distinguishes Prostatic Small-Cell Carcinoma fromMost Prostatic Adenocarcinomas (2015) (0)
Re: Prevalence, Impact, and Risk Factors for Hospital-Acquired Conditions after Major Surgical Resection for Cancer: A NSQIP Analysis. (2016) (0)
Influence of Department Leadership on Scholarly Productivity and Research Funding in Academic Urology. (2021) (0)
An expression-guided screen for small molecules targeting aggressive prostate cancer. (2014) (0)
OUTCOMES OF VERY‐HIGH‐RISK PROSTATE CANCER: VALIDATION STUDY FROM 3 INSTITUTIONS OVER 10 YEARS: MP20‐18 (2017) (0)
PD27-02 IS CAPSULAR ABUTMENT ON MRI A PREDICTOR OF EXTRAPROSTATIC EXTENSION (EPE) ON RADICAL PROSTATECTOMY? (2022) (0)
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies. (2023) (0)
Re: For Single Dosing, Levofloxacin is Superior to Ciprofloxacin when Combined with an Aminoglycoside in Preventing Severe Infections after Prostate Biopsy. (2016) (0)
Percent genome alteration and outcomes after radical prostatectomy in African American men. (2019) (0)
High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments (2022) (0)
MP44-11 DETECTION OF SUBSEQUENT CLINICALLY SIGNIFICANT PROSTATE CANCER FOLLOWING INITIAL DECISION TO FORGO BIOPSY IN THE MULTIPARAMETRIC MRI ERA (2023) (0)
Using Attention-based Deep Learning to Predict ERG:TMPRSS2 Fusion Status in Prostate Cancer from Whole Slide Images (2022) (0)
Re: National Trends in Hospitalization from Indwelling Urinary Catheter Complications, 2001-2010. (2015) (0)
Re: Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine. (2013) (0)
Patient Positioning; Incision/Port Placement (2014) (0)
Effect of local therapy on the systemic anti-tumor response in prostate cancer. (2016) (0)
Re: Prediction of Bacteriuria Based on Clinical or Laboratory Parameters in Patients with Indwelling Ureteral Stents before Ureterorenoscopy Should Not Substitute for Urine Cultures. (2020) (0)
Re: a case-control study of chronic prostatitis/chronic pelvic pain syndrome and colorectal cancer. (2013) (0)
"Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. (2018) (0)
Re: Urinary Tract Infections in Older Men. (2016) (0)
Re: Evaluation of Perioperative Prophylaxis with Fosfomycin Tromethamine in Ureteroscopic Stone Removal: An Investigator-Driven Prospective, Multicenter, Randomized, Controlled Study. (2019) (0)
MP07-20 DEVELOPMENT AND VALIDATION OF GENOMIC SIGNATURE THAT PREDICTS ADT TREATMENT FAILURE (2016) (0)
Re: Racial and ethnic disparities in healthcare-associated infections in the United States, 2009-2011. (2015) (0)
Re: Renal Transplant Recipients Receiving Loop Diuretic Therapy Have Increased Urinary Tract Infection Rate and Altered Medullary Macrophage Polarization Marker Expression. (2019) (0)
MP40-18 PROSTATE CANCER DETECTION RATE OF TRANSPERINEAL PROSTATE BIOPSY: COGNITIVE VERSUS SOFTWARE FUSION, A MULTICENTER ANALYSIS (2023) (0)
MP66-16 ANATOMIC TUMOR LOCATION NOT RACIAL BACKGROUND IMPACTS ETS FAMILY TRANSCRIPTION FACTOR AND SPINK1 EXPRESSION IN PROSTATE CANCER. (2015) (0)
Infection and Inflammation of the Genitourinary Tract. (2001) (0)
Re: Uropathogenic Escherichia coli Induces Chronic Pelvic Pain. (2016) (0)
Re: Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients with Elevated Serum Prostate-Specific Antigen is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. (2017) (0)
Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. (2022) (0)
Re: Superselective Vesical Artery Embolization in the Management of Intractable Hematuria Secondary to Hemorrhagic Cystitis. (2020) (0)
Pathologic Lymph Node-positive Prostate Cancer: Some Answers … with Many More Questions. (2015) (0)
1066 The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy (2016) (0)
History of Urology: History Forum IFRI-03 THE HISTORY OF PROSTATE CANCER FROM ANTIQUITY: REVIEW OF PALEOPATHOLOGICAL STUDIES (2016) (0)
The influence of decision aids on prostate cancer screening preferences: A randomized survey study. (2018) (0)
Re: development of sustained-release antibacterial urinary biomaterials through using an antimicrobial as an organic modifier in polyurethane nanocomposites. (2013) (0)
Re: Antibacterial Susceptibilities of Escherichia coli from Community-Acquired Urinary Tract Infections in the Faroe Islands, Associations with Antibacterial Sales, and Comparison with Iceland and Denmark. (2017) (0)
Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials (2023) (0)
Abstract 2546: Predictive value of prostate health index (PHI) in multi-parametric MRI in an ethnically diverse cohort (2021) (0)
Response to Takahashi. (2022) (0)
National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis. (2019) (0)
Re: the effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. (2014) (0)
Infection and Inflammation of the Genitourinary Tract. (2021) (0)
805 THE MATRICELLULAR PROTEIN HEVIN IS INCREASED IN THE MAJOR PELVIC GANGLION FOLLOWING CAVERNOUS NERVE INJURY AND INHIBITS NEURITE OUTGROWTH (2012) (0)
238: The Molecular Basis of Early Prostate Development (2006) (0)
Re: Formalin Disinfection of Prostate Biopsy Needles May Reduce Post-Biopsy Infectious Complications. (2017) (0)
MP21-11 IS LOW SOCIOECONOMIC STATUS ASSOCIATED WITH WORSE TUMOR BIOLOGY FOR MEN WITH PROSTATE CANCER? (2018) (0)
822: The Influence of Recurrent Prostate Cancer on Serum Testosterone Levels (2005) (0)
Re: A method to assess seasonality of urinary tract infections based on medication sales and Google trends. (2015) (0)
THE IMPACT OF RACE ON PERCEPTIONS OF ANXIETY AFTER LOCAL THERAPY FOR PROSTATE CANCER: MP69‐19 (2017) (0)
MP68-02 NEUROIMMUNE REGULATION OF METASTATIC PROSTATE CANCER-ASSOCIATED BONE PAIN (2019) (0)
Re: acute bacterial prostatitis in humans: current microbiological spectrum, sensitivity to antibiotics and clinical findings. (2014) (0)
Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer. (2017) (0)
Re: Descriptive analysis of 30-day readmission after inpatient surgery discharge in the veterans health administration. (2015) (0)
The impact of race on perceptions of anxiety after radical prostatectomy. (2017) (0)
2240 PERFORMANCE OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY (2013) (0)
Re: Small Intestine Early Innate Immunity Response during Intestinal Colonization by Escherichia coli Depends on its Extra-Intestinal Virulence Status. (2017) (0)
Infection and inflammation of the genitourinary tract: Editorial comment (2014) (0)
PD42-06 INTERMEDIATE-TERM OUTCOMES IN MEN WITH VERY HIGH RISK PROSTATE CANCER (2016) (0)
Re: Sustained Influence of Infections on Prostate-Specific Antigen Concentration: An Analysis of Changes over 10 Years of Follow-up. (2020) (0)
Re: voided midstream urine culture and acute cystitis in premenopausal women. (2014) (0)
Tec family kinases in T cell receptor signaling (2001) (0)
Re: Incidence and Management of Uncomplicated Recurrent Urinary Tract Infections in a National Sample of Women in the United States. (2017) (0)
A Putative Nononcogene Addiction Gene Target and Marker for Radiosensitivity in High-Risk Prostate Cancer (2012) (0)
Re: Variability of Transrectal Ultrasound-Guided Prostate Biopsy Prophylactic Measures (2014) (0)
Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report (2016) (0)
Re: Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-Related Symptoms-Outcomes from a Network Meta-Analysis. (2020) (0)
Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis. (2019) (0)
Re: Electrical Microcurrent to Prevent Conditioning Film and Bacterial Adhesion to Urological Stents (2012) (0)
Re: Comparison of Fosfomycin against Fluoroquinolones for Transrectal Prostate Biopsy Prophylaxis: An Individual Patient-Data Meta-Analysis. (2018) (0)
Re: antibiotics and observation have a similar impact on asymptomatic patients with a raised PSA. (2012) (0)
Re: Potential Burden of Antibiotic Resistance on Surgery and Cancer Chemotherapy Antibiotic Prophylaxis in the USA: A Literature Review and Modelling Study. (2016) (0)
Re: The "Rule of W" in Urology: Testing Surgical Dictum. (2020) (0)
Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer (2023) (0)
Re: Does Size Matter? Measured and Modeled Effects of Suprapubic Catheter Size on Urinary Flow. (2019) (0)
GENDER DIFFERENCES IN UROLOGICAL SUBSPECIALTIES: MP86‐18 (2017) (0)
MP09-01 THE ROLE OF PROPHYLACTIC ANTIBIOTICS IN TRANSPERINEAL PROSTATE BIOPSY: A SYSTEMATIC REVIEW AND METANALYSIS (2022) (0)
Re: A Population-Based Cohort Study of the Impact of Infectious Complications Requiring Hospitalization after Prostate Biopsy on Radical Prostatectomy Surgical Outcomes. (2019) (0)
Re: Urinary Tract Infections following Radical Cystectomy and Urinary Diversion: A Review of 1133 Patients. (2019) (0)
Tsai and De Morais et al 1 Cyclin D 1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas (2015) (0)
Re: Escherichia coli Antimicrobial Resistance Increased Faster among Geriatric Outpatients Compared with Adult Outpatients in the USA, 2000-10 (2014) (0)
Re: The Effect of Sevoflurane versus Desflurane on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Transurethral Excision of a Bladder Tumour: A Randomized Controlled Trial. (2017) (0)
Re: Fibrin Glue Therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. (2016) (0)
Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multi-Modal Deep Learning with Digital Histopathology (2022) (0)
Chromatin relaxation is a feature of advanced prostate cancer (2016) (0)
Re: Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. (2018) (0)
THE IMPACT OF SOCIOECONOMIC STATUS, RACE, AND INSURANCE TYPE ON THE RISK OF NEWLY DIAGNOSED METASTATIC PROSTATE CANCER IN THE UNITED STATES: PD03‐07 (2017) (0)
MP90-10 SERUM TESTOSTERONE LEVELS PRIOR TO PROSTATE CANCER DIAGNOSIS (2016) (0)
Re: Cranberry Products and Prevention of Urinary Tract Infections (2014) (0)
MP07-03 PRIMARY TUMOR ANDROGEN RECEPTOR SIGNALING AS A PREDICTOR OF CASTRATE RESISTANCE (2016) (0)
Re: Incidence and Management of Extended-Spectrum Beta-Lactamase and Quinolone-Resistant Escherichia coli Infections after Prostate Biopsy. (2015) (0)
Re: Seven hours to adequate antimicrobial therapy in urosepsis using isothermal microcalorimetry. (2015) (0)
Re: Current Management of Radiation Cystitis: A Review and Practical Guide to Clinical Management. (2020) (0)
Re: An Implementation Guide to Reducing Overtreatment of Asymptomatic Bacteriuria. (2020) (0)
Re: Effect of Increased Daily Water Intake in Premenopausal Women with Recurrent Urinary Tract Infections: A Randomized Clinical Trial. (2020) (0)
Development and Validation of Genomic Signature That Predicts Androgen Deprivation Therapy Treatment Failure. (2016) (0)
Re: The revival of fosfomycin. (2012) (0)
Re: Development and Validation of a Nomogram Predicting Recurrence Risk in Women with Symptomatic Urinary Tract Infection. (2015) (0)
Re: Multiparametric MRI Appearances of Primary Granulomatous Prostatitis. (2020) (0)
47 Effect of local therapy on the systemic anti-tumor response in prostate cancer (2016) (0)
MP6-09 MOLECULAR AND CLINICAL CHARACTERIZATION OF 1,577 PRIMARY PROSTATE CANCER TUMORS REVEALS NOVEL CLINICAL AND BIOLOGICAL INSIGHTS INTO ITS SUBTYPES (2015) (0)
PD57-07 FACTORS PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN PIRADS 4 LESIONS (2022) (0)
Re: Effect of a Hospital-Associated Urinary Tract Infection Reduction Policy on General Surgery Patients. (2019) (0)
An inside view of student culture at a liberal arts college (1992) (0)
Infection and Inflammation of the Genitourinary Tract. (2021) (0)
Association between frailty and low testosterone among men undergoing oncologic surgery (2022) (0)
Re: First Experience in the UK of Treating Women with Recurrent Urinary Tract Infections with the Bacterial Vaccine Uromune®. (2018) (0)
Utilization of genetic testing in men with advanced prostate cancer (2023) (0)
Optimal therapy in localized prostate cancer: an unfolding story. (2009) (0)
Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer (2018) (0)
1116: Incidence of Local Recurrence and Port Site Metastasis after Laparoscopic Radical Nephroureterectomy (2006) (0)
MP06-03 RACE BASED DISPARITIES IN GENE EXPRESSION AND MUTATIONS IN BLADDER CANCER (2018) (0)
Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria. (2019) (0)
VARIATIONS IN THE PATIENT EXPERIENCE AT AN ACADEMIC UROLOGY DEPARTMENT: HOW SURVEY RESULTS DRIVE LIKELIHOOD TO RECOMMEND METRICS: MP32‐10 (2017) (0)
WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. (2023) (0)
Corrigendum to: National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. (2019) (0)
Abstract A066: Performance of the prostate health index (PHI) assay in black men (2020) (0)
Re: Active surveillance: does serial prostate biopsy increase histological inflammation? (2014) (0)
Re: Long-Term Experience of Hyperbaric Oxygen Therapy for Refractory Radio- or Chemotherapy-Induced Haemorrhagic Cystitis. (2016) (0)
Treatment patterns and outcomes in prostate cancer patients tested with Decipher in SEER. (2022) (0)
Re: Laparoscopic nephrectomy in xanthogranulomatous pyelonephritis: 7-year single-surgeon outcome. Re: Xanthogranulomatous pyelonephritis: presentation and management in the era of laparoscopy. (2012) (0)
TRENDS IN USE OF ANDROGEN DEPRIVATION THERAPY WITH RADIATION IN HIGH AND VERY HIGH RISK PROSTATE CANCER PATIENTS: MP76‐06 (2017) (0)
MP22-04 HOW FREQUENTLY ARE PELVIC LYMPH NODES IRRADIATED IN MEN RECEIVING PRIMARY EXTERNAL BEAM RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER? (2018) (0)
Re: Antagonists of Growth Hormone-Releasing Hormone Inhibit Proliferation Induced by Inflammation in Prostatic Epithelial Cells. (2018) (0)
Electron Solvation in Finite Systems : Femtosecond Dynamics of Iodide z ( Water ) n Anion Clusters (1999) (0)
LB-S&T-10 THREE INTRINSIC SUBTYPES OF PROSTATE CANCER WITH DISTINCT PATHWAY ACTIVATION PROFILES DIFFER IN PROGNOSIS AND TREATMENT RESPONSE (2016) (0)
Delineation of inferior vena caval anatomy with 3-dimensional computerized tomography reconstruction. (2008) (0)
Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa). (2019) (0)
Re: Incidence of Urinary Tract Infection among Siblings of Children with Vesicoureteral Reflux. (2018) (0)
Re: Impact of Asymptomatic Prostatitis on Re-Operations due to Urethral Stricture or Bladder Neck Contracture Developed After TUR-P (2013) (0)
MP1-11 VALIDATION OF THE DECIPHER® PROSTATE CANCER CLASSIFIER IN INTERMEDIATE TO HIGH RISK MEN TREATED WITH RADICAL PROSTATECTOMY BUT WITHOUT ADDITIONAL THERAPY UPON PSA RISE (2015) (0)
Novel Associations Between the Immune Landscape of Prostate Cancer and Postoperative Radiation Response (2017) (0)
Re: Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. (2012) (0)
Re: Evaluation of Targeted Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy: A Prospective Cohort Trial. (2018) (0)
MP17-14 COST-EFFECTIVENESS OF TRANSPERINEAL VERSUS TRANSRECTAL PROSTATE BIOPSY FOR THE DIAGNOSIS OF PROSTATE CANCER (2021) (0)
Re: Clinical validation of integrated nucleic acid and protein detection on an electrochemical biosensor array for urinary tract infection diagnosis. (2013) (0)
PD15-11 INSTRUMENT LIFE FOR ROBOT ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY: ARE TEN LIVES FOR MOST INSTRUMENTS JUSTIFIED? (2015) (0)
Re: Pyelonephritis: What are the Present Day Causative Organisms and Antibiotic Susceptibilities? (2014) (0)
Infection and Inflammation of the Genitourinary Tract. (2020) (0)
Re: Chronic Prostatitis and Comorbid Non-Urological Overlapping Pain Conditions: A Co-Twin Control Study. (2018) (0)
Re: Screening for Asymptomatic Bacteriuria in Adults: US Preventive Services Task Force Recommendation Statement. (2020) (0)
Re: Bacteria on Urine Microscopy is Not Associated with Systemic Infection in Patients with Obstructing Urolithiasis. (2019) (0)
Renal parenchymal tumors (2019) (0)
MP44-17 USE OF DECIPHER PROSTATE BIOPSY TEST IN MEN WITH FAVORABLE RISK DISEASE UNDERGOING CONSERVATIVE MANAGEMENT IN THE SEER REGISTRY (2023) (0)
Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer (2018) (0)
Factors Predicting Clinically Significant Prostate Cancer on PIRADS 3 lesions (2022) (0)
Role of WNT Pathway Mutations within Oligometastatic Castration-Sensitive Prostate Cancer (2022) (0)
PD57-06 FACTORS PREDICTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN PIRADS 3 LESIONS (2022) (0)
Re: A randomized trial of computer kiosk-expedited management of cystitis in the emergency department. (2012) (0)
SPINK1 expression and outcomes postprostatectomy in race-specific cohorts. (2019) (0)
Re: Efficacy of Tamsulosin, Oxybutynin, and Their Combination in the Control of Double-J Stent-Related Lower Urinary Tract Symptoms. (2018) (0)
Phases, Not Stages: The Life Cycle of College Students. (1989) (0)
Re: the prevalence and natural history of urinary symptoms among recreational ketamine users. (2013) (0)
Re: Medical Directive for Urinary Catheter Removal by Nurses on General Medical Wards. (2016) (0)
PD08-03 LONG-TERM TUMOR NECROSIS FACTOR-ALPHA INHIBITOR USE INCREASES THE RISK OF RENAL CELL CARCINOMA (2023) (0)
MP17-01 DIFFERENTIAL TRANSCRIPTOMIC INDICATORS OF POTENTIAL THERAPEUTIC RESPONSE TO TARGETED THERAPY FOR AJCC IIC+ LOCALIZED PROSTATE CANCER WITH DECIPHER ≥0.95 (2023) (0)
Re: Weight Gain and Obesity in Infants and Young Children Exposed to Prolonged Antibiotic Prophylaxis (2017) (0)
MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY (2018) (0)
Re: Predictive value of antimicrobial susceptibility from previous urinary tract infection in the treatment of re-infection. (2012) (0)
MP11-19 IT'S ALL IN THE NAME: DOES NOMENCLATURE FOR INDOLENT PROSTATE CANCER IMPACT MANAGEMENT AND ANXIETY? (2021) (0)
MP51-06 TUMOR-INFILTRATING T-CELLS IN PROSTATE CANCER FROM MEN OF AFRICAN ANCESTRY (AA) CORRELATE WITH LOW ANDROGEN RECEPTOR ACTIVITY AND INCREASED METASTATIC RISK (2020) (0)
Prostate Cancer Tumor Volume and Genomic Risk (2023) (0)
Re: IL-17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients. (2012) (0)
Re: histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish Prostate Cancer Screening Trial. (2014) (0)
Re: Antimicrobial Resistance in Women with Urinary Tract Infection in Primary Care: No Relation with Type 2 Diabetes Mellitus. (2019) (0)
MP1-04 EVALUATION OF GENOMIC SIGNATURES IN INTERMEDIATE TO HIGH RISK MEN TREATED WITH RADICAL PROSTATECTOMY BUT WITHOUT ADDITIONAL THERAPY UPON PSA RISE (2015) (0)
Re: Th1-Th17 cells contribute to the development of uropathogenic Escherichia coli-induced chronic pelvic pain. (2014) (0)
Re: Cost-Effectiveness of Hydrophilic-Coated Intermittent Catheters Compared with Uncoated Catheters in Canada: A Public Payer Perspective (2018) (0)
Re: Etiology of Symptomatic Urethritis in Men and Association with Sexual Behaviors. (2017) (0)
TNF-alpha immunosuppressive use and future malignancy risk. (2021) (0)
694 PROSTATIC BUDDING IN DEVELOPMENT IS MEDIATED BY A RHOA / ROCK DEPENDENT PATHWAY (2010) (0)
Re: The Use of Intravesical Gentamicin to Treat Recurrent Urinary Tract Infections in Lower Urinary Tract Dysfunction. (2019) (0)
MP61-11 SPINK1 DEFINES A MOLECULAR SUBTYPE OF PROSTATE CANCER MEN WITH MORE RAPID PROGRESSION FROM BIOCHEMICAL RECURRENCE TO DEATH IN AN AT RISK, NATURAL HISTORY COHORT (2015) (0)
MP51-18 DIFFERENTIAL EXPRESSION PROFILING OF LNCRNA IN PRIMARY PROSTATE CANCER BASED ON BLACK AND WHITE RACE (2020) (0)
Re: Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. (2013) (0)
Re: Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection. (2013) (0)
Re: Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis? (2015) (0)
Re: Incidence and Microbiology of Post-Operative Infections after Radical Cystectomy and Ureteral Stent Removal; A Retrospective Cohort Study. (2019) (0)
Re: Septic shock and adequacy of early empiric antibiotics in the emergency department. (2015) (0)
PD17-05 CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PIRADS 5 LESIONS AND NEGATIVE BIOPSIES (2022) (0)
Re: The Potential Impact of Excluding Funguria from the Surveillance Definition of Catheter-Associated Urinary Tract Infection. (2016) (0)
Re: Ketamine Cystitis: Practical Considerations in Management. (2016) (0)
MP33-10 IDENTIFYING THE MECHANISTIC CONNECTION BETWEEN INFLAMMATORY BOWEL DISEASE AND PROSTATE CANCER: A LARGE-SCALE GENE EXPRESSION ANALYSIS (2021) (0)
Infection and Inflammation of the Genitourinary Tract. (2020) (0)
Re: Photoselective Vaporization of the Bladder for the Management of Radiation Cystitis-Technique and Initial Outcomes. (2020) (0)
Re: A Single Dose of Intraoperative Antibiotics is Sufficient to Prevent Urinary Tract Infection During Ureteroscopy. (2017) (0)
Re: Safety and Efficacy of Intravesical Alum for Intractable Hemorrhagic Cystitis: A Contemporary Evaluation. (2018) (0)
MP41-17 MODIFIED 2005 ISUP GRADING IS ASSOCIATED WITH SIGNIFICANT UPGRADE AND BETTER PREDICTS METASTASIS (2014) (0)
Positive LymphNodes at Radical Prostatectomy : The JohnsHopkinsHospital 30-Year Experience (2013) (0)
MP69-12 PREDICTORS OF SURGICAL CURE IN MEN WITH VERY HIGH RISK PROSTATE CANCER (2016) (0)
MP40-04 LONG-TERM TUMOR NECROSIS FACTOR-ALPHA INHIBITOR USE DECREASES THE RISK OF PROSTATE CANCER (2023) (0)
MP09-11 TRENDS IN SURGICAL MANAGEMENT OF HIGH-RISK PROSTATE CANCER: EVIDENCE OF AN EVOLVING TREATMENT PARADIGM (2016) (0)
Abstract PO-100: Association of B7-H3 expression with racial ancestry, immune cell density and AR activation in prostate cancer (2022) (0)
Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification. (2014) (0)
Re: Effectiveness of Acupuncture on Chronic Prostatitis-Chronic Pelvic Pain Syndrome Category IIIB Patients: A Prospective, Randomized, Nonblinded, Clinical Trial. (2015) (0)
MP07-01 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT PROSTATE CANCER DEATH IN HIGH RISK PATIENTS (2016) (0)
Re: antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location. (2012) (0)
Antimicrobial prophylaxis for urological procedures (2019) (0)
PD34-09 COMPARISON OF PATHOLOGIC OUTCOMES IN MEN WITH FAVORABLE-RISK PROSTATE CANCER UNDERGOING DELAYED SURGERY AFTER ACTIVE SURVEILLANCE VERSUS IMMEDIATE SURGERY (2015) (0)
Re: SGLT-2 Inhibitors and the Risk of Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2018) (0)
Candidate surrogate endpoints in advanced prostate cancer: Aggregate meta-analysis of 143 randomized trials. (2022) (0)
Risk factors for postprostate biopsy infection. (2019) (0)
Re: Management of Bacteriuria in Veterans Affairs Hospitals. (2017) (0)
THE UNCOUPLING OF DIAGNOSIS AND IMMEDIATE TREATMENT IN VERY LOW AND LOW RISK PROSTATE CANCER: A NATIONAL PERSPECTIVE: MP14‐01 (2017) (0)
POTENTIAL ROLE FOR NESTIN, A NEURAL STEM CELL MARKER, IN THE PATHOPHYSIOLOGY OF INJURY AND REPAIR OF THE CAVERNOUS NERVE (2009) (0)
Re: screening urine analysis before bacille calmette-guérin instillation does not reduce the rate of infectious complications. (2013) (0)
Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer. (2016) (0)
MP09-12 FREEDOM FROM BIOCHEMICAL RECURRENCE AND METASTASIS IN MEN WITH VERY HIGH RISK PROSTATE CANCER TREATED AT A TERTIARY CENTER: VALIDATION OF A NEW RISK STRATUM (2016) (0)
Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model (2017) (0)
Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer. (2020) (0)
MP82-01 THE INFLUENCE OF DECISION AIDS ON PROSTATE CANCER SCREENING PREFERENCES (2018) (0)
Re: Comparing the Efficacy of Tolterodine and Gabapentin versus Placebo in Catheter Related Bladder Discomfort after Percutaneous Nephrolithotomy: A Randomized Clinical Trial. (2019) (0)
PD44-03 MOLECULAR ASSOCIATIONS WITH PLASMA CELL CONTENT IN PROSTATE CANCER (2021) (0)
Percent genome alteration predicts adverse oncologic outcomes after radical prostatectomy in African American men: A profile of cancer genomics by racial ancestry (2019) (0)
Re: Effects of Ureteral Stents on Risk of Bacteriuria in Renal Allograft Recipients (2014) (0)
PD05-06 PERCENT GENOME ALTERATION PREDICTS ADVERSE ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY IN AFRICAN AMERICAN MEN: A PROFILE OF CANCER GENOMICS BY RACIAL ANCESTRY (2019) (0)
MP64-18 RISK OF PROSTATE CANCER IN MEN WITH CHRONIC INFLAMMATORY CONDITIONS (2020) (0)
Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design. (2020) (0)
Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging (2010) (0)
Re: Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain. (2013) (0)
Re: α-Blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. (2013) (0)
Re: Clinical Characteristics of Postoperative Febrile Urinary Tract Infections after Ureteroscopic Lithotripsy. (2019) (0)
PD31-08 FLUOROQUINOLONE RESISTANCE IN THE RECTAL CARRIAGE OF MEN IN AN ACTIVE SURVEILLANCE COHORT (2014) (0)
Re: Acute Pyelonephritis in Adults (2018) (0)
MP60-02 TRANSCRIPTOMICS CAN PREDICT HOMOLOGOUS RECOMBINATION DEFICIENCY IN PROSTATE CANCER (2021) (0)
Re: Antibiotic Coating of the Artificial Urinary Sphincter (AMS 800): Is it Worthwhile? (2019) (0)
Re: Outpatient urological procedures in antibiotic-naïve patients with bladder cancer with asymptomatic bacteriuria. (2013) (0)
299 A CONTEMPORARY ANALYSIS OF CLINICAL OUTCOMES FOR MEN WITH ADENOCARCINOMA OF THE PROSTATE WITH SEMINAL VESICLE INVASION (PT3B) AFTER RADICAL PROSATECTOMY (2010) (0)
Re: Association of Screening and Treatment for Preoperative Asymptomatic Bacteriuria with Postoperative Outcomes among US Veterans. (2019) (0)
Re: The Effect of Broader, Directed Antimicrobial Prophylaxis Including Fungal Coverage on Perioperative Infectious Complications after Radical Cystectomy. (2016) (0)
Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues. (2016) (0)
Re: population structure and uropathogenic virulence-associated genes of faecal Escherichia coli from healthy young and elderly adults. (2012) (0)
Re: Animal Experimental Study to Test Application of Intelligent Pressure Control Device in Monitoring and Control of Renal Pelvic Pressure during Flexible Ureteroscopy (2016) (0)
MP13-16 THE COST OF PROSTATE BIOPSIES AND THEIR COMPLICATIONS: A SUMMARY OF DATA ON ALL MEDICARE FEE-FOR-SERVICE PATIENTS OVER TWO YEARS (2019) (0)
PD34-07 NATURAL HISTORY OF PROGRESSION TO PSA RECURRENCE AND METASASIS AMONG AT RISK MEN FOLLOWING RADICAL PROSTATECTOMY (2014) (0)
1638 EFFECTS OF 5-ALPHA REDUCTASE INHIBITOR USE IN MONITORED MEN WITH VERY-LOW RISK PROSTATE CANCER (2011) (0)
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination (2017) (0)
Re: Frequency of Recurrent Urinary Tract Infection in Patients with Pelvic Organ Prolapse. (2015) (0)
Re: A case-control study on the association between chronic prostatitis/chronic pelvic pain syndrome and erectile dysfunction. (2013) (0)
Re: prognostic factors for recent-onset interstitial cystitis/painful bladder syndrome. (2013) (0)
Re: prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. (2012) (0)
BONE MINERAL CONTENT AND PROSTATE CANCER: THE SEED AND SOIL HYPOTHESIS (2009) (0)
Re: Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection. (2014) (0)
Book Review Smith's Textbook of Endourology Second edition. Edited by Arthur D. Smith, Gopal Badlani, and Demetrius Bagley, with eight others. 972 pp., illustrated, plus index, with CD-ROM. Hamilton, Ont., Canada, BC Decker, 2007. $299.95. 978-1-55009-365-0 (2008) (0)
Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes. (2015) (0)
Abstract 462: Using attention-based deep multiple instance learning to identify key genetic alterations in prostate cancer from whole slide images (2022) (0)
SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy (2019) (0)
Re: Multiparametric MRI Findings of Granulomatous Prostatitis after Intravesical bacillus Calmette-Guérin Therapy in a Patient Undergoing Active Surveillance. (2016) (0)
Re: Clinical and Microbiological Characteristics of Spontaneous Acute Prostatitis and Transrectal Prostate Biopsy-Related Acute Prostatitis: Is Transrectal Prostate Biopsy-Related Acute Prostatitis a Distinct Acute Prostatitis Category? (2016) (0)
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial (2023) (0)
Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer (2019) (0)
Re: Ibuprofen versus Pivmecillinam for Uncomplicated Urinary Tract Infection in Women-A Double-Blind, Randomized Non-Inferiority Trial. (2019) (0)
Re: Morphological plasticity promotes resistance to phagocyte killing of uropathogenic Escherichia coli. (2011) (0)
PD54-02 CHARACTERIZATION OF PSMA AND 18F-FLUCICLOVINE TRANSPORTER GENE EXPRESSION IN LOCALIZED PROSTATE CANCER (2020) (0)
Re: Correlation of Inflammatory Mediators in Prostatic Secretion with Chronic Prostatitis and Chronic Pelvic Pain Syndrome. (2019) (0)
Re: Chlorhexidine Daily Bathing: Impact on Health Care-Associated Infections Caused by Gram-Negative Bacteria. (2015) (0)
Novel Genomic Biomarker Panel Predictive of Aggressive Disease in African American Men with Prostate Cancer (2018) (0)
LONGTERM ONCOLOGICAL EFFICACY OF LAPAROSCOPIC RADICAL NEPHRECTOMY FOR CLINICALLY LOCALISED RCC >7CM (2008) (0)
Re: Comparison of Fosfomycin against Fluoroquinolones for Transrectal Prostate Biopsy Prophylaxis: An Individual Patient-Data Meta-Analysis. (2018) (0)
430 Molecular and clinical characterization of 1,577 primary prostate cancers reveal novel clinical and biological insights into subtypes (2015) (0)
Re: Continuous Low-Dose Antibiotic Prophylaxis for Adults with Repeated Urinary Tract Infections (AnTIC): A Randomised, Open-Label Trial. (2019) (0)
Re: Adaptation of Escherichia coli Traversing from the Faecal Environment to the Urinary Tract. (2017) (0)
A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy (2016) (0)
Re: Wind, Water, Wound, Walk-Do the Data Deliver the Dictum? (2016) (0)
Abstract 3520: Immunogenomic landscape of grade group 5 prostate cancer predicts risk of lethal outcomes and may inform treatment response (2020) (0)
Abstract A32: Characterizing patterns of cytokine coexpression with immune checkpoint markers in CD4 and CD8 tumor-infiltrating lymphocytes (2020) (0)
Re: The Effectiveness of Prophylactic Antibiotics with Oral Levofloxacin against Post-Shock Wave Lithotripsy Infectious Complications: A Randomized Controlled Trial. (2017) (0)
Re: Timing of surgical antibiotic prophylaxis and the risk of surgical site infection. (2013) (0)
Editorial comment. (2014) (0)
Re: Association between Rectal Colonization with Highly Resistant Gram-Negative Rods (HR-GNRs) and Subsequent Infection with HR-GNRs in Clinical Patients: A One Year Historical Cohort Study. (2020) (0)
Genitourinary Pathology (2016) (0)
Re: Policies for Replacing Long-Term Indwelling Urinary Catheters in Adults. (2017) (0)
Re: Effectiveness of Acupuncture on Chronic Prostatitis-Chronic Pelvic Pain Syndrome Category IIIB Patients: A Prospective, Randomized, Nonblinded, Clinical Trial. (2015) (0)
305 EVOLUTION OF THE CLINICAL PRESENTATION OF MEN UNDERGOING RADICAL PROSTATECTOMY FOR HIGH-RISK PROSTATE CANCER (2011) (0)
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men. (2023) (0)
1118: Five Year Oncological Outcome after Laparoscopic Radical Nephroureterectomy (2006) (0)
Re: Preoperative Urine Culture is Unnecessary in Asymptomatic Men prior to Prostate Needle Biopsy. (2019) (0)
1377P Transcriptomic based indicators of potential therapeutic response to targeted therapy among 50,000 men with localized prostate cancer (2022) (0)
PD28-10 COMBINATORIAL THERAPEUTIC APPROACHES WITH PD-1 INHIBITION IN PROSTATE CANCER (2016) (0)
767 PATHOLOGICAL AND ONCOLOGIC OUTCOMES FOR MEN WITH POSITIVE LYMPH NODES AT RADICAL PROSTATECTOMY: 30-YEAR EXPERIENCE FROM A SINGLE INSTITUTION (2012) (0)
Re: DamX Controls Reversible Cell Morphology Switching in Uropathogenic Escherichia coli (2017) (0)
Re: Premenopausal Women with Recurrent Urinary Tract Infections Have Lower Quality of Life. (2019) (0)
Re: Prevalence of fluoroquinolone-resistant Escherichia coli before and Incidence of acute bacterial prostatitis after prostate biopsy. (2012) (0)
The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy. (2014) (0)
Re: Abnormal Urinalysis Results are Common, Regardless of Specimen Collection Technique, in Women without Urinary Tract Infections. (2017) (0)
MP22-01 THE ASSOCIATION BETWEEN FRAILTY, LOW TESTOSTERONE, AND POSTOPERATIVE OUTCOMES AMONG MEN UNDERGOING TRANSURETHRAL RESECTION OF BLADDER TUMOR (2023) (0)
Re: predictive value of escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis. (2013) (0)
Re: Symptomatic Treatment of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting: Randomised, Double Blind Trial. (2018) (0)
MP1-12 COMPARATIVE ANALYSIS OF AFRICAN AMERICAN AND EUROPEAN AMERICAN MEN USING A PROSTATE CANCER GENOMIC CLASSIFIER (2015) (0)
Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes (2015) (0)
Abstract 1502: Three intrinsic subtypes of prostate cancer with distinct pathway activation profiles differ in prognosis and treatment response (2016) (0)
Clinical-Genomic Sub-classification of High-Risk Prostate Cancer: Implications for Tailoring Therapy and Clinical Trial Design (2020) (0)
Re: spectrum of bacterial colonization associated with urothelial cells from patients with chronic lower urinary tract symptoms. (2014) (0)
Re: Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-Induced Hemorrhagic Cystitis. (2018) (0)
Re: Clinical Outcomes after Ureteroscopic Lithotripsy in Patients Who Initially Presented with Urosepsis: Matched Pair Comparison with Elective Ureteroscopy. (2016) (0)
Re: Antimicrobial Prophylaxis for Children with Vesicoureteral Reflux (2014) (0)
MP53-17 CLINICAL VALIDATION OF THE 2005 ISUP GLEASON GRADING SYSTEM IN A COHORT OF INTERMEDIATE AND HIGH RISK MEN UNDERGOING RADICAL PROSTATECTOMY (2015) (0)
The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy. (2013) (0)
Re: The Efficacy of Pregabalin for Prevention of Catheter-Related Bladder Discomfort: A Prospective, Randomized, Placebo-Controlled Double-Blind Study. (2016) (0)
Re: Effect of Body Surface Decolonisation on Bacteriuria and Candiduria in Intensive Care Units: An Analysis of a Cluster-Randomised Trial. (2016) (0)
Re: Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. (2012) (0)
Corrigendum to definitive and sustained increase in prostate cancer metastases in the United States. (2022) (0)
Re: Analysis of Factors' Association with Risk of Postoperative Urosepsis in Patients Undergoing Ureteroscopy for Treatment of Stone Disease. (2018) (0)
431 Validation of the Decipher® prostate cancer classifier in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise (2015) (0)
Re: Development and Characterization of a Stable Adhesive Bond between a Poly(dimethylsiloxane) Catheter Material and a Bacterial Biofilm Resistant Acrylate Polymer Coating. (2017) (0)
encouraging, suggesting that future screening protocols may be improved through the integration of genetic information. Is this ready for prime time? Not yet—prospective validation studies are necessary to determine whether genotype adjusted PSA thresholds will improve clinical outcomes. (2011) (0)
1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS) (2022) (0)
CHANGES IN LEAN MUSCLE MASS ASSOCIATED WITH NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: PD62‐08 (2017) (0)
Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer (2023) (0)
Study protocol for a prospective, multi-centered randomized controlled trial comparing pelvic fascia-sparing radical prostatectomy with conventional robotic-assisted prostatectomy: The PARTIAL trial. (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With E. Marilyn Schaeffer?

E. Marilyn Schaeffer is affiliated with the following schools:

Northwestern University
University of Chicago
Johns Hopkins University
Oregon Health & Science University
University of Pennsylvania